Showing results (191-200 of 237) with videos related to
Sort By:
Pageof 24
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|July 2, 2013
Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in JapanHideo Koh, Masayuki Hino, Kensuke Ohta, et al.International Journal of Hematology|July 4, 2008
A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in JapanKeisuke Miyazawa, Kazuma Ohyashiki, Akio Urabe, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 10, 2017
BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutationAyae Amemiya, Yoshikazu Ito, Yasunori Ishibashi, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 17, 2012
[Assessment of health-related quality of life in cancer outpatients treated with chemotherapy]Tomohisa Yokoyama, Yui Kurokawa, Rinako Kani, et al.International Journal of Hematology|August 13, 2013
Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trialYuzuru Kanakura, Kazuma Ohyashiki, Tsutomu Shichishima, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|September 21, 2014
Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trialTakahiko Nakane, Kazuo Tamura, Masayuki Hino, et al.Leukemia Research|December 15, 2010
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET systemTetsuzo Tauchi, Masahiro Kizaki, Shinichiro Okamoto, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 9, 2016
Musculoskeletal pain after stopping tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a questionnaire surveySeiichiro Katagiri, Tetsuzo Tauchi, Yuu Saito, et al.International Journal of Hematology|January 3, 2020
Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study GroupHiroki Yamaguchi, Naoki Takezako, Kazuteru Ohashi, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 14, 2015
[Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib]Seiichiro Katagiri, Tetsuzo Tauchi, Tomohiro Umezu, et al.Pageof 24